ROX NHS ester, 5-isomer
Cat. # | Quantity | Price | Lead time | Buy this product |
---|---|---|---|---|
11220 | 1 mg | $110.00 | in stock | |
21220 | 5 mg | $210.00 | in stock | |
41220 | 25 mg |
$410.00
|
in stock | |
51220 | 50 mg |
$695.00
|
in stock | |
61220 | 100 mg |
$1190.00
|
in stock |
ROX (rhodamine X) is a bright rhodamine dye for ROX channel. Carboxy rhodamines come as two isomers. This product is a derivative of pure 5-carboxy-ROX.
Absorption and emission spectra of ROX dye

Customers also purchased with this product
BDP 558/568 NHS ester
BDP 558/568 is a fluorophore for the yellow region of the spectrum. Like other BDP dyes, this fluorophore has high fluorescence quantum yield, brightness, and photostability.BDP 576/589 NHS ester
BDP 576/589 NHS ester (BODIPY™ 576/589 analog) is a bright hydrophobic dye with emission in the orange spectrum range. It can be used in fluorescence anisotropy assays.get free express delivery
DusQ1 CPG 500
Controlled pore glass (CPG) 500 solid support for synthesis of oligonucleotides with 3’-terminal DusQ1 quencher. Compatible with standard deblocking conditions.get free express delivery
General properties
Appearance: | dark red solid |
Mass spec M+ increment: | 516.2 |
Molecular weight: | 631.67 |
CAS number: | 209734-74-7; 344402-35-3 |
Molecular formula: | C37H33N3O7 |
Solubility: | good in DMF, DMSO |
Quality control: | NMR 1H, HPLC-MS (80%) |
Storage conditions: | Storage: 12 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate. |
MSDS: | Download |
Product specifications |
Spectral properties
Excitation/absorption maximum, nm: | 570 |
ε, L⋅mol−1⋅cm−1: | 93000 |
Emission maximum, nm: | 591 |
Fluorescence quantum yield: | 1.0 |
CF260: | 0.62 |
CF280: | 0.49 |
Product citations
- Konopka, C.J.; Wozniak, M.; Hedhli, J.; Ploska, A.; Schwartz-Duval, A.; Siekierzycka, A.; Pan, D.; Munirathinam, G.; Dobrucki, I.T.; Kalinowski, L.; Dobrucki, L.W. Multimodal imaging of the receptor for advanced glycation end-products with molecularly targeted nanoparticles. Theranostics, 2018, 8(18), 5012–5024. doi: 10.7150/thno.24791
The count of items is incorrect.
